DRUG-TREATMENT OF PANIC DISORDER

被引:14
作者
ROSENBERG, R
机构
[1] Institute for Basic Research in Psychiatry, Department of Biological Psychiatry, Psychiatric Hospital in Aarhus, University Hospital, Risskov
来源
PHARMACOLOGY & TOXICOLOGY | 1993年 / 72卷 / 06期
关键词
D O I
10.1111/j.1600-0773.1993.tb01343.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Drug treatment of panic disorder is reviewed with focus on recent controlled studies. The efficacy of alprazolam, a triazolobenzodiazepine, and imipramine, a tricyclic antidepressant, has consistently been demonstrated, but there is reasonable evidence that other benzodiazepines or antidepressants might also be effective if equipotent doses are used. Most controlled studies demonstrate drug efficacy on several psychopathological symptoms, including the core symptom panic attacks. Limited evidence indicates that alprazolam may be more efficacious in treating panic attacks than avoidance behaviour, and the reverse when imipramine is concerned. Drug efficacy appears to be most consistently documented in moderately to severely ill panic patients. The benzodiazepines are better tolerated than antidepressants in terms of patient acceptance, and the improvement sets in faster with benzodiazepines. In the presence of depressive symptoms considered secondary to panic attacks and/or agoraphobia, both types of drugs appear efficacious. Difficulty discontinuing high-dose benzodiazepine treatment remains the most important side effect of the treatment but sedation can, like anticholinergic side effects of the tricyclic antidepressants, be troublesome, thereby diminishing patient compliance. The role of newly developed antidepressants with a more specific mode of action and milder side effects awaits evaluation in controlled trials.
引用
收藏
页码:344 / 353
页数:10
相关论文
共 73 条
[1]   DRUG-TREATMENT OF PANIC DISORDER - EARLY RESPONSE TO TREATMENT AS A PREDICTOR OF FINAL OUTCOME [J].
ALBUS, M ;
LECRUBIER, Y ;
MAIER, W ;
BULLER, R ;
ROSENBERG, R ;
HIPPIUS, H .
ACTA PSYCHIATRICA SCANDINAVICA, 1990, 82 (05) :359-365
[3]  
BALESTRIERI M, 1989, PSYCHIAT DEV, V7, P337
[4]  
BALLENGER JC, 1988, ARCH GEN PSYCHIAT, V45, P413
[5]  
BRADWEJN J, 1991, ARCH GEN PSYCHIAT, V48, P603
[6]  
BREIER A, 1986, ARCH GEN PSYCHIAT, V43, P1029
[7]   CLINICAL-SIGNIFICANCE OF THE SPARTEINE-DEBRISOQUINE OXIDATION POLYMORPHISM [J].
BROSEN, K ;
GRAM, LF .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 36 (06) :537-547
[8]   CHRONOLOGY OF PANIC AND AVOIDANCE, AGE OF ONSET IN PANIC DISORDER, AND PREDICTION OF TREATMENT RESPONSE - A REPORT FROM THE CROSS-NATIONAL COLLABORATIVE PANIC STUDY [J].
BULLER, R ;
MAIER, W ;
GOLDENBERG, IM ;
LAVORI, PW ;
BENKERT, O .
EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, 1991, 240 (03) :163-168
[9]  
CHARNEY DS, 1986, ARCH GEN PSYCHIAT, V43, P1042
[10]   THE RELATIONSHIP OF ALPRAZOLAM DOSE TO STEADY-STATE PLASMA-CONCENTRATIONS [J].
CIRAULO, DA ;
ANTAL, EJ ;
SMITH, RB ;
OLSON, DR ;
GOLDBERG, DA ;
RAND, EH ;
RASKIN, RB ;
PHILLIPS, JP ;
SHADER, RI ;
GREENBLATT, DJ .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1990, 10 (01) :27-32